# Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma

> **NCT00004022** · PHASE2 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute**

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** autologous tumor cell vaccine
- **BIOLOGICAL:** muromonab-CD3
- **BIOLOGICAL:** therapeutic autologous lymphocytes
- **PROCEDURE:** surgical procedure

## Key facts

- **NCT ID:** NCT00004022
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-06
- **Primary completion:** 2004-01
- **Final completion:** 2004-01
- **Target enrollment:** — (—)
- **Last updated:** 2013-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004022, "Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00004022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*